CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING
Cantex Pharmaceuticals announced that four abstracts featuring azeliragon, a RAGE inhibitor, will be presented at the 2024 ASCO Annual Meeting in Chicago. Azeliragon, a once-a-day pill, is being investigated for its potential in treating various difficult-to-treat cancers. The abstracts cover studies on azeliragon's safety and therapeutic effects in metastatic pancreatic cancer, its use in combination with temozolomide and radiotherapy for newly diagnosed glioblastoma, its role in reducing cardiotoxicity in women with early breast cancer, and its effectiveness when combined with stereotactic radiation therapy in patients with brain metastases. The meeting provides a platform for showcasing clinical progress to leading oncology researchers globally.
- Cantex Pharmaceuticals will present four abstracts at the prestigious 2024 ASCO Annual Meeting, increasing visibility in the oncology community.
- Azeliragon shows potential as a treatment for difficult-to-treat cancers like metastatic pancreatic cancer and glioblastoma.
- The drug demonstrates versatility by being studied in various combinations and settings, such as with temozolomide and radiotherapy, and stereotactic radiation therapy.
- Involvement in high-impact research on cardiotoxicity reduction in early breast cancer patients highlights azeliragon's broader therapeutic potential.
- No conclusive therapeutic benefits have been established yet for azeliragon, as the studies are in early phases (phase I/II).
- The presented studies are focused on safety and preliminary evidence, signaling a long road ahead before potential market approval.
- Patients are refractory to first-line treatments, indicating a challenging patient population that may complicate efficacy results.
- Participation in multiple early-stage trials may increase research and development expenses without guaranteed success.
"The 2024 ASCO Annual Meeting represents an important opportunity to meet with the leading oncology researchers from around the world and showcase the progress of azeliragon clinical investigations at leading cancer centers in several difficult-to-treat cancers," said Stephen G. Marcus, M.D., Cantex's Chief Executive Officer.
2024 ASCO Annual Meeting Abstracts:
Title: A phase I/II open label study to assess safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer.
Abstract #: TPS4212
Title: Azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II CAN-201 NDG trial design.
Abstract #: TPS2096
Title: RAGE inhibition to decrease cancer therapy related cardiotoxicity in women with early breast cancer (RAGE).
Abstract #: TPS619
Title: A phase I/II study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metastases (ADORATION).
Abstract #: TPS2093
About Azeliragon
Azeliragon is an orally administered capsule, taken once daily, that inhibits interactions of the receptor for advanced glycation end products (known as RAGE) with certain ligands, including HMGB1 and S100 proteins in the tumor microenvironment. Azeliragon was discovered by and originally under development for Alzheimer's disease by vTv Therapeutics Inc. (NASDAQ: VTVT) from which Cantex licensed worldwide rights to azeliragon. Clinical safety data from these trials, involving more than 2000 individuals dosed for periods up to 18 months, indicate that azeliragon is very well tolerated.
Cantex has ongoing Phase II clinical trials in pancreatic cancer, glioblastoma, brain metastasis, breast cancer, and a Phase 3 trial in hospitalized patients with pneumonia to prevent acute kidney injury. These trials are based on azeliragon's robust preclinical data as well as its extensive clinical safety information from randomized placebo-controlled clinical trials.
Azeliragon has
About Cantex Pharmaceuticals, Inc.
Cantex Pharmaceuticals, Inc. is a privately held, clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed. To learn more please visit www.cantex.com.
About vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates, led by cadisegliatin (TTP399), a potentially transformative treatment for the reduction of hypoglycemic episodes in type 1 diabetes patients. To learn more please visit vtvtherapeutics.com.
Contact Information:
Cantex Pharmaceuticals, Inc.
Stephen G. Marcus, M.D.
+1 954-315-3660
info@cantex.com
Juan F. Rodriguez
+1 954-315-3660
info@cantex.com
Tiberend Strategic Advisors, Inc.
Investors
Daniel Kontoh-Boateng
+1 862-213-1398
dboateng@tiberend.com
Media
Casey McDonald
+1 646-577-8520
cmcdonald@tiberend.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cantex-pharmaceuticals-announces-four-abstracts-to-be-presented-featuring-azeliragon-at-2024-asco-annual-meeting-302155456.html
SOURCE Cantex Pharmaceuticals, Inc.
FAQ
What is Cantex Pharmaceuticals presenting at the 2024 ASCO Annual Meeting?
What is azeliragon?
What types of cancer studies involve azeliragon?
When and where is the 2024 ASCO Annual Meeting?
What is the significance of the 2024 ASCO Annual Meeting for Cantex Pharmaceuticals?
